Results 231 to 240 of about 123,214 (256)
Some of the next articles are maybe not open access.
The Importance of Heart Rate in Heart Failure and Reduced Ejection Fraction
Journal of Cardiovascular Nursing, 2018Background: Heart failure with reduced ejection fraction (HFrEF) is a progressive, chronic, and burdensome cardiovascular condition. It is associated with limiting symptoms, such as dyspnea and fatigue; a decline in functional capacity; and premature mortality and hospitalization. In heart failure (HF) management, heart rate is
Marilyn A, Prasun, Nancy M, Albert
openaire +2 more sources
Developments in Heart Failure With Reduced Ejection Fraction
JAMA, 2020Ricky D, Turgeon, Arden R, Barry
openaire +4 more sources
Dapagliflozin for patients with heart failure and reduced ejection fraction
JAAPA, 2022ABSTRACT The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients
openaire +2 more sources
Heart Failure With Reduced Ejection Fraction
Journal of the American College of Cardiology, 2021Clyde W. Yancy +2 more
openaire +2 more sources
Heart Failure with Reduced Ejection Fraction
Heart Failure Clinics, 2023Terri L. Allison, Beth Towery Davidson
openaire +3 more sources
Redefining Heart Failure With a Reduced Ejection Fraction
JAMA, 2019Javed, Butler +2 more
openaire +2 more sources
Heart Failure with Reduced Ejection Fraction
2022Prashant Rao, Marwa A. Sabe
openaire +2 more sources
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
New England Journal of Medicine, 2021Nikolaus Marx +2 more
exaly